AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor
This poster was presented at the 2023 AACR Annual Meeting.
To read the full study report download the poster.
This poster was presented at the 2023 AACR Annual Meeting.
To read the full study report download the poster.